Combination Therapy Inhibiting EGFR and c-Met Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including surgery, chemotherapy, and radiotherapy, have limitations such as incomplete tissue removal, side effects, and drug resistance, necessitating the development of combination therapies to achieve synergistic effects and overcome resistance.
Innovation Solution
A combination therapy involving the co-administration of an EGFR antagonist and an anti-c-Met antibody to inhibit the actions of HGF/c-Met and HER1/EGFR, overcoming resistance and achieving significant synergistic effects in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy drugs are used to treat cancer, then cancer cell growth is inhibited, but drug resistance develops and side effects occur
Solution Approach 1:
The patent combines two different therapeutic approaches: EGFR antagonist therapy and anti-c-Met antibody therapy. This combination targets two different signaling pathways (EGFR and c-Met) that are both involved in cancer cell growth and survival, thereby overcoming drug resistance that develops when using a single therapy. The synergistic effect of the combination therapy enhances cancer cell inhibition while reducing the harmful effects of individual therapies.
2Quantity of substance
If surgery is used to remove cancer tissue, then tumor mass is reduced, but newly-generated tissues cannot be completely removed
Solution Approach 1:
The patent replaces the mechanical approach of surgery with a biochemical therapeutic approach using EGFR antagonists and anti-c-Met antibodies. These drugs target the molecular signaling pathways that drive cancer cell proliferation and survival, providing a more comprehensive treatment that can reach cancer cells throughout the body, including those that cannot be surgically removed.
3Reliability
If radiotherapy is used to treat cancer, then neoplastic tissues are destroyed, but serious side effects occur and effectiveness is limited to radiation-sensitive tumors
Solution Approach 1:
The patent changes the therapeutic parameter from physical radiation energy to biochemical targeting using EGFR antagonists and anti-c-Met antibodies. This biochemical approach selectively targets cancer cells expressing specific receptors (EGFR and c-Met) while sparing normal cells, thereby reducing side effects and expanding applicability to a broader range of cancer types regardless of radiation sensitivity.
Data Source
AI summary
A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.